HC Wainwright Increases Selecta Biosciences (NASDAQ:SELB) Pr

Selecta Biosciences (NASDAQ:SELB – Get Rating) had its price target raised by equities research analysts at HC Wainwright from $4.00 to $5.00 in a research note issued to investors on Wednesday, The Fly reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 244.83% […]

Related Keywords

Selecta Biosciences , Carsten Brunn , Needham Company , Eqis Capital Management Inc , Selecta Biosciences Inc , Canaccord Genuity Group , Pricet Rowe Associates Inc , Virtu Financial , Prudential Financial Inc , Beacon Pointe Advisors , Selecta Biosciences Company Profile , Get Rating , Capital Management , Synthetic Vaccine Particles , Selecta Biosciences Daily , Nasdaq Selb , Selb , Medical , Boost Price Target , Hc Wainwright ,